Explore how synthetic biology and AI are transforming drug development, from engineered yeast producing vaccine adjuvants to AI-driven molecular discovery.
An in-depth analysis of the 2007 biopharmaceutical landscape, exploring the paradox of record drug pipelines alongside declining FDA approvals.